Vilsbøll, Tina

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 157

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

Storgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 155

Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 144

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 142

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 120

FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest

Søberg, S., Andersen, E. S., Dalsgaard, N. B., Jarlhelt, I., Hansen, N. L., Hoffmann, N., Vilsbøll, T., Chenchar, A., Jensen, M., Grevengoed, T. J., et al. (2018) · Molecular Metabolism

Fibroblast Growth Factor ResearchAlcohol Consumption and Health Effects

Cited by 94

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 92

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 89

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology

Pharmacology and Obesity TreatmentSchizophrenia research and treatment

Cited by 88

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., et al. (2022) · Cell Reports Medicine

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 81

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 80

How glucagon-like peptide 1 receptor agonists work

Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 71

GIP and GLP-1 receptor antagonism during a meal in healthy individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 68

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients

Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 66

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica

Psoriasis: Treatment and PathogenesisSkin Diseases and Diabetes

Cited by 65

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 62

Neuroprotective Mechanisms of Glucagon‐like Peptide‐1‐based Therapies in Ischaemic Stroke: A Systematic Review based on Pre‐Clinical Studies

Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology

Neuroprotection in Cerebral IschemiaAcute Ischemic Stroke Management

Cited by 61

Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 59

Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes

Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 56

Effective interventions in preventing gestational diabetes mellitus: A systematic review and meta-analysis

Takele, W. W., Vesco, K. K., Josefson, J., Redman, L. M., Hannah, W., Bonham, M. P., Chen, M., Chivers, S. C., Fawcett, A. J., Grieger, J. A., et al. (2024) · Communications Medicine

Gestational Diabetes Research and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 55

Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

Christensen, R. H., Hansen, C. S., von Scholten, B. J., Jensen, M. T., Pedersen, B. K., Schnohr, P., Vilsbøll, T., Rossing, P., & Jørgensen, P. G. (2019) · Diabetes Obesity and Metabolism

Cardiovascular Disease and AdiposityCardiovascular Function and Risk Factors

Cited by 55

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity

Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 51

Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo-controlled, crossover trial (GLIMLINA)

Christensen, A. S., Hædersdal, S., Støy, J., Storgaard, H., Kampmann, U., Forman, J. L., Seghieri, M., Holst, J. J., Hansen, T., Knop, F. K., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 48

Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes

Rhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 47